The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Non‐Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co‐Delivery of Cas9 mRNA and sgRNA
Open accessAbstract
CRISPR/Cas is a revolutionary gene editing technology with wide‐ranging utility. The safe, non‐viral delivery of CRISPR/Cas components would greatly improve future therapeutic utility. We report the synthesis and development of zwitterionic amino lipids (ZALs) that are uniquely able to (co)deliver long RNAs including Cas9 mRNA and sgRNAs. ZAL nanoparticle (ZNP) delivery of low sgRNA doses (15 n m ) reduces protein expression by >90 % in cells. In contrast to transient therapies (such as RNAi), we show that ZNP delivery of sgRNA enables permanent DNA editing with an indefinitely sustained 95 % decrease in protein expression. ZNP delivery of mRNA results in high protein expression at low doses in vitro (<600 pM) and in vivo (1 mg kg −1 ). Intravenous co‐delivery of Cas9 mRNA and sgLoxP induced expression of floxed tdTomato in the liver, kidneys, and lungs of engineered mice. ZNPs provide a chemical guide for rational design of long RNA carriers, and represent a promising step towards improving the safety and utility of gene editing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, lipid-mediated nanoparticle (LNP) delivery has been used to transport CRISPR-Cas components in the form of either mRNA/sgRNA or preassembled RNPs into tissues 71-74 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [71]
In the citing paper
“With i.v. injection of ZAL nanoparticles containing Cas9 mRNA and sgRNA, the stop gene sequences in Rosa26tdTomato mice were edited, leading to strong tdTO fluorescent signal in the liver, lungs and kidneys.[214]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [214]
In the citing paper
“In another study, Miller et al. reported a non-viral vector based on zwitterionic amino lipids to deliver Cas9 mRNA and sgRNAs. In contrast to transient therapies, they showed permanent editing of LoxP gene in genetically engineered mice containing a homozygous Rosa26 promoter Lox-Stop-Lox tdTomato (tdTO) cassette after intravenous administration [105].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Flagged first, then by citations
1 of the 45 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–540 of 540
Biomaterials for gene editing therapeutics
Shim, G., Kim, D., Le, Q., Byun, J., Park, J.-W., & Oh, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102983-1.00008-9
Bioanalytical Challenges and Strategies of Crispr Genome Editors
Hölttä, M., Nitsch, R., & Henderson, N. (2021) · Bioanalysis · doi:10.4155/bio-2020-0215
RNA delivery for cancer gene therapy
Öncül, S., Amero, P., Rodriguez‐Aguayo, C., Sood, A. K., Călin, G. A., & Lopez‐Berestein, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00004-x
Genome Editing in Crops Via Homology-Directed Repair Using a Geminivirus-Based CRISPR/Cas9 System
Hameed, A., Faazal, B., Awais, M., & Naveed, A. (2022) · Springer eBooks · doi:10.1007/978-981-19-0600-8_6
Messenger RNA Therapeutics: Start of a New Era in Medicine
Jain, S., George, A. J., Sharma, V., Singh, G., & Gupta, V. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_3
CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
Ma, L., Jang, L., Chen, J., Song, J. J., Yang, D., Zhang, J., Chen, Y., & Xu, J. (2019) · Journal of Visualized Experiments · doi:10.3791/59512-v
Deng, H., Liu, Y., & Sun, S. (2022) · Wiley eBooks · doi:10.1002/9781119692799.ch12
Comparison of Non-viral Delivery Vehicles for CRISPR/Cas9 Therapies
Henry, D. (2023) · STEM Fellowship Journal · doi:10.17975/sfj-2023-006
Delivery of Rna Drugs: Beyond the Liver, More than VaccinePreprint
Elnaggar, M. G., He, Y., & Yeo, Y. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4657914
Engineering Nucleic Acid Structures for Programmable Intracellular Biocomputation
Wu, N., Hao, P., Fan, C., & Zhao, Y. (2024) · doi:10.1002/9783527840816.ch18
IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy
Jolly, K. J., & Zhang, F. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.04.004
Concepts and definitions in microbiology and nanotechnology in plant sciences
Kumar, N., Vishwakarma, K., & Lateef, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18822-0.00001-3
Harnessing Nanopolysaccharides for Sustainable Agriculture and Environmental Protection
Santhosha, D., Vanitha, K., Dineshmohan, S., Mavulati, S. C., & Tiwari, O. N. (2025) · Springer eBooks · doi:10.1007/978-981-97-9873-5_12
Challenges in developing gene therapy against Duchenne muscular dystrophy
Kurshakova, E. V., Levchenko, O. A., & Лавров, А. В. (2025) · Genes and Cells · doi:10.17816/gc641931 · Cited by 1
Streiber, M., Liu, N., Simon, L., Adermann, F., Bachmann, V., Hoeppener, S., Schubert, S., Werz, O., Lapinte, V., Morille, M., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5200072
Применение технологии CRISPR/Cas9 при наследственных заболеваниях почек
Ван, Ш. (2025) · Рецепт · doi:10.34883/pi.2025.28.2.004
Wilson, D. W., Gouda, M., Meester, F. D., Takahashi, T., Singh, R. B., Tuli, H. S., & Buttar, H. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22300-6.00035-8
CRISPR-Cas9 Mediated Knockout of Apoptotic Genes in Human Stem Cells: A Functional Study
Hamza, Z. S., Temimi, T. A., Al-Oudah, G. A., & Shareffi, K. A. A. (2025) · Journal of Biomedicine and Biochemistry · doi:10.57238/jbb.2025.7432.1148
Gao, Z., Lin, K., Gong, Y., Zhao, Y., & Zhang, S. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c02069
Self-citationNanocarriers for the delivery of the CRISPR/Cas9 system
Hwang, S., Ko, H., Lee, H.-Y., & Choi, J. H. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2598332 · Cited by 1
Singh, S., Chaudhary, A., Patel, A., Trivedi, M., Johri, P. K., & Tiwari, R. (2026) · Nanotechnology in the life sciences · doi:10.1007/978-981-95-4913-9_6
Fast mRNA delivery in vitro and in vivo enabled by magnetic responsive lipid nanoparticles
Lin, Y., Wu, J., Liu, Z., Song, R., Li, Z., Zhang, R., & Li, B. (2026) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-026-01690-1
Enhanced Intracellular Stability and Translation Efficiency of mRNA Drugs by a 2‐arm mRNA Platform
Teng, X., Lin, J., Zhang, Q., Zhang, X., Dai, Y., & Li, J. (2026) · Advanced Science · doi:10.1002/advs.75244
Gao, Y., Chen, Y., Hu, Z., Wang, Z., Sun, D., Wu, C., Shuai, Q., & Yan, Y. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c05610
Jiang, J., & Yan, Y. (2026) · ChemBioChem · doi:10.1002/cbic.70413
Debski, A. C., Gorick, C. M., Breza, V. R., Song, J., & Price, R. J. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100535
Zaman, W., & Ayaz, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146467
A surface-mediated hydrogel patch for localized CRISPR genome editing in inflammatory wound therapy
Feng, S., Li, Y., Ye, T., Su, P., Li, X., & Wang, W. (2026) · Materials Horizons · doi:10.1039/d6mh01100d
RNA delivery to the corneal endothelium using charge-altering releasable transporters
Wang, S. K., Li, Z., Shah, S. H., Edwards, Q. A., Bouffard, R., Hines, E. S., Imventarza, J. A., Korte, S., Lawrence, M. S., Song, E., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady8161
Yang, Y., Song, T., Huang, K., Huang, H., Zhao, M., & Li, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091094
Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption
Losa, M., Rajmane, P., Stanaway, M., Coons, M., Munoz, A., Garish, V., Tan, B., Thompson, M., Gonzalez, R., Churchward, G., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103084 · Cited by 1
Novel therapies in Alzheimer’s disease
Pavăl, D., Căpățînă, O., & Stănculete, M. F. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.026
Nanotechnology and Genetically Modified Organisms for Agricultural Sustainability
Fernández-Bunster, G. C. (2026) · doi:10.1002/9781119808527.ch17
Zu, Y., Wang, H., Han, X., Wu, X., & Chen, L. (2026) · Genetics · doi:10.1093/genetics/iyag245
The CRISPR/Cas technology landscape: From molecular mechanisms to multidisciplinary applications
Liu, Z., Yang, Y., Li, Z., Li, P., Jia, J., Qiao, X., Su, Y., Qin, Y., Wang, H., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102484
CRISPR-Based Genome Editing and Delivery Systems: Advances, Challenges and Future Directions
Kaur, A., Chanan, R., Sharma, M., Sharma, S., & Sharma, D. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016405
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
Chen, R., Zhou, H., Wu, Q., & Gong, C. (2026) · ACS Nano · doi:10.1021/acsnano.6c12154
Ramasamy, Y., & Raju, I. (2026) · RSC Pharmaceutics · doi:10.1039/d6pm00104a
Karim, M. E., Holl, M. M. B., Corrie, S. R., & Chowdhury, E. H. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01085-w
Metadata
- Authors
- Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J.
- Affiliations
- Harold C. Simmons Comprehensive Cancer Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center Department of Biochemistry Dallas TX 75390 USA
- Corresponding author
- Siegwart, Daniel J.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-12-16
- Volume
- 56
- Issue
- 4
- Pages
- 1059-1063
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- PMC
- PMC5521011
- OpenAlex
- W2560987571
- Cited by
- 540
- References
- 45
- Citations by year
- 2026: 35 · 2025: 39 · 2024: 47 · 2023: 48 · 2022: 66 · 2021: 86 · 2020: 79 · 2019: 59 · 2018: 55 · 2017: 24 · 2016: 1
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA190525)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- CRISPR gene editing, lipid nanoparticles, Cas9 mRNA, single guide RNA, co-delivery, in vivo gene editing, loxP
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Lipids, RNA, Messenger, Molecular Structure, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
